康方生物依若奇单抗获批上市；百克生物一季度净利润下降98.24%

Policy Developments - The head of the National Medical Products Administration, Li Li, conducted research in Jiangsu to support the development of the pharmaceutical industry, emphasizing the need for tailored strategies and full guidance for key products [2] Drug and Device Approvals - Kangfang Biotech's Ilumya (依若奇) monoclonal antibody has been approved for the treatment of moderate to severe plaque psoriasis in adults, marking it as China's first domestically approved dual-target monoclonal antibody [3] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS-9813 capsules, a class 1 innovative drug for treating progressive pulmonary fibrosis, with a total R&D investment of approximately 98.27 million yuan [4] - Jiukang Biotech announced the receipt of multiple medical device registration certificates, enhancing its product range without significant immediate impact on operations [5] - Renfu Pharmaceutical's subsidiary received approval for HWS116 injection, a new biological product for treating advanced solid tumors, with a cumulative R&D investment of about 38 million yuan [6] Financial Reports - Baike Biotech reported a 39.96% decline in revenue to 162 million yuan and a 98.24% drop in net profit to 1.0643 million yuan, primarily due to decreased sales of shingles vaccines [7] - Haichen Pharmaceutical achieved a 36.43% increase in revenue to 143 million yuan and a 12.57% rise in net profit to 15.037 million yuan [9] - Meikang Biotech's annual report indicated a revenue of 1.742 billion yuan, a 7.61% decrease, while net profit rose by 0.56% to 258 million yuan [10] Capital Market Activities - Xiamen Junde Pharmaceutical completed nearly 100 million yuan in Series A financing, aimed at registering and producing a weight-loss oral device and accelerating R&D for innovative drug-device combinations [11] - Qise Lian Biotech announced the completion of its first round of financing, which will be used to accelerate platform development and product innovation in iPSC therapies [12] Industry Developments - Hainan University announced the release of self-developed brain-computer interface (BCI) core technologies and products, achieving full-chain technological autonomy in the BCI field, with performance on par with international top products [13] - The global brain-computer interface market is projected to grow from approximately 2.62 billion USD in 2024 to 12.4 billion USD by 2034, with a compound annual growth rate of 17.4% from 2025 to 2034 [14] Regulatory and Market Alerts - Changyao Holdings announced a one-day suspension of its stock due to negative net assets and continuous losses, with its stock name changing to "*ST Changyao" [15] - Zhongyao Holdings received a regulatory letter from the Shenzhen Stock Exchange regarding inaccuracies in its 2023 financial disclosures, leading to potential accountability for its executives [16][17] - Huaren Health announced plans by shareholders to reduce their holdings by up to 1.5% due to funding arrangements [18]